Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y4Z2

UPID:
NGN3_HUMAN

ALTERNATIVE NAMES:
Class A basic helix-loop-helix protein 7; Protein atonal homolog 5

ALTERNATIVE UPACC:
Q9Y4Z2; Q5VVI0; Q6DJX6; Q9BY24

BACKGROUND:
The protein Neurogenin-3, alternatively named Protein atonal homolog 5, is crucial for neurogenesis and the differentiation of pancreatic endocrine cells. It functions as a transcriptional regulator, essential for the activation of NEUROD1 and the specification of pancreatic endocrine cell types.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Neurogenin-3 could open doors to potential therapeutic strategies for congenital malabsorptive diarrhea, a condition directly linked to mutations in the gene encoding this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.